Diabetes Care：终末糖基化产物（AGE）水平升高与视网膜病变进展相关

2012-04-25 高晓方译医学论坛网

　　美国学者的一项研究表明，在1型糖尿病患者中，免疫复合物中（IC）中终末糖基化产物（AGE）-LDL和氧化LDL（oxLDL）水平升高与晚期视网膜病变进展风险升高相关。论文于2011年4月17日在线发表于《糖尿病护理》（Diabetes Care）杂志。　　此项研究共纳入517例糖尿病患者，并测定了IC中的AGE-LDL和oxLDL水平。利用立体眼底摄像评估视网膜病变。利用Cox比

　　美国学者的一项研究表明，在1型糖尿病患者中，免疫复合物中（IC）中终末糖基化产物（AGE）-LDL和氧化LDL（oxLDL）水平升高与晚期视网膜病变进展风险升高相关。论文于2011年4月17日在线发表于《糖尿病护理》（Diabetes Care）杂志。

　　此项研究共纳入517例糖尿病患者，并测定了IC中的AGE-LDL和oxLDL水平。利用立体眼底摄像评估视网膜病变。利用Cox比例风险模型评估AGE-LDL-IC和oxLDL-IC对视网膜病变进展的影响。随访时间超过16年。

　　结果显示，在未校正模型中，基线AGE-LDL-IC和oxLDL-IC高水平可显著预测糖尿病视网膜病变的进展转归。对治疗组、视网膜病变人群、1型糖尿病持续时间以及基线白蛋白排泄率（AER）、糖化血红蛋白和早期糖尿病视网膜病变治疗研究（ETDRS）评分等研究设计变量进行校正后，AGE-LDL-IC和oxLDL-IC水平每升高一个标准差（SD）与增生型糖尿病视网膜病变（PDR）形成风险升高47%和45%相关，并且均与严重非增生型视网膜病变进展风险升高37%相关。由于初级和次级人群存在结果差异，因此依据视网膜病变人群进行分层分析。对于AGE-LDL-IC，在初级人群中进展至PDR的危险比为2.38，并且在次级人群中减弱。oxLDL-IC的结果与之相似。

　　链接：　　

Lopes-Virella MF, Baker NL, Hunt KJ, Lyons TJ, Jenkins AJ, Virella G; the DCCT/EDIC Study Group.High Concentrations of AGE-LDL and Oxidized LDL in Circulating Immune Complexes Are Associated With Progression of Retinopathy in Type 1 Diabetes.Diabetes Care. 2012 Apr 17.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (6)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1759132, encodeId=8d6a1e591320a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Jul 11 04:16:00 CST 2012, time=2012-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636494, encodeId=8cd5163649452, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jun 01 20:16:00 CST 2012, time=2012-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900943, encodeId=8b621900943c3, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu May 17 18:16:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269767, encodeId=07ba1269e6704, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318276, encodeId=87e213182e6a1, content=<a href='/topic/show?id=b5dde6644b1' target=_blank style='color:#2F92EE;'>#糖基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76644, encryptionId=b5dde6644b1, topicName=糖基化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413851, encodeId=c7a914138517b, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
2012-07-11 ms5439512287675881

#BET#

68 0
[GetPortalCommentsPageByObjectIdResponse(id=1759132, encodeId=8d6a1e591320a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Jul 11 04:16:00 CST 2012, time=2012-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636494, encodeId=8cd5163649452, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jun 01 20:16:00 CST 2012, time=2012-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900943, encodeId=8b621900943c3, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu May 17 18:16:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269767, encodeId=07ba1269e6704, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318276, encodeId=87e213182e6a1, content=<a href='/topic/show?id=b5dde6644b1' target=_blank style='color:#2F92EE;'>#糖基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76644, encryptionId=b5dde6644b1, topicName=糖基化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413851, encodeId=c7a914138517b, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
2012-06-01 ms9608593228839890

#DIA#

61 0
[GetPortalCommentsPageByObjectIdResponse(id=1759132, encodeId=8d6a1e591320a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Jul 11 04:16:00 CST 2012, time=2012-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636494, encodeId=8cd5163649452, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jun 01 20:16:00 CST 2012, time=2012-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900943, encodeId=8b621900943c3, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu May 17 18:16:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269767, encodeId=07ba1269e6704, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318276, encodeId=87e213182e6a1, content=<a href='/topic/show?id=b5dde6644b1' target=_blank style='color:#2F92EE;'>#糖基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76644, encryptionId=b5dde6644b1, topicName=糖基化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413851, encodeId=c7a914138517b, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
2012-05-17 木头人513

#Diabetes#

73 0
[GetPortalCommentsPageByObjectIdResponse(id=1759132, encodeId=8d6a1e591320a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Jul 11 04:16:00 CST 2012, time=2012-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636494, encodeId=8cd5163649452, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jun 01 20:16:00 CST 2012, time=2012-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900943, encodeId=8b621900943c3, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu May 17 18:16:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269767, encodeId=07ba1269e6704, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318276, encodeId=87e213182e6a1, content=<a href='/topic/show?id=b5dde6644b1' target=_blank style='color:#2F92EE;'>#糖基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76644, encryptionId=b5dde6644b1, topicName=糖基化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413851, encodeId=c7a914138517b, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
2012-04-27 zutt

#视网膜#

68 0
[GetPortalCommentsPageByObjectIdResponse(id=1759132, encodeId=8d6a1e591320a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Jul 11 04:16:00 CST 2012, time=2012-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636494, encodeId=8cd5163649452, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jun 01 20:16:00 CST 2012, time=2012-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900943, encodeId=8b621900943c3, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu May 17 18:16:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269767, encodeId=07ba1269e6704, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318276, encodeId=87e213182e6a1, content=<a href='/topic/show?id=b5dde6644b1' target=_blank style='color:#2F92EE;'>#糖基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76644, encryptionId=b5dde6644b1, topicName=糖基化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413851, encodeId=c7a914138517b, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
2012-04-27 lfyang

#糖基化#

74 0
[GetPortalCommentsPageByObjectIdResponse(id=1759132, encodeId=8d6a1e591320a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Jul 11 04:16:00 CST 2012, time=2012-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636494, encodeId=8cd5163649452, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jun 01 20:16:00 CST 2012, time=2012-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900943, encodeId=8b621900943c3, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu May 17 18:16:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269767, encodeId=07ba1269e6704, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318276, encodeId=87e213182e6a1, content=<a href='/topic/show?id=b5dde6644b1' target=_blank style='color:#2F92EE;'>#糖基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76644, encryptionId=b5dde6644b1, topicName=糖基化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413851, encodeId=c7a914138517b, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Fri Apr 27 02:16:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
2012-04-27 zhanfl

#视网膜病变#

56 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

糖尿病

Diabetes Care：终末糖基化产物（AGE）水平升高与视网膜病变进展相关

相关资讯

科室

工具

服务